MMRGlobal Subsidiary Receives Clinical Trials Patent, as University of Texas Southwestern Medical Center & the University of Manchester Validate Patient Engagement in Clinical Trials

LOS ANGELES, CA--(Marketwired - Jul 14, 2014) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), today announced that it has received a new patent from the United States Patent and Trademark Office entitled "Electronic Health Records in Clinical Trials." The newly issued patent, U.S. Patent No. 8,775,212, opens the door to completely new revenue generating opportunities for the Company through sales and licensing of MMR's Personal Health Record ("PHR") products and services and other patented intellectual property ("Patented IP") to Contract Research Organizations ("CROs") and pharmaceutical companies conducting clinical trials. According to, there are currently 170,766 studies occurring in all 50 states and in 187 countries being conducted by numerous CROs, universities and pharmaceutical companies. CROs, Big Pharma and pharmaceutical start-ups are consistently looking for ways to reduce costs and speed up the clinical trial process. MMR's products, services and patented IP are designed to help reduce trial costs and shorten trial times. Accordingly, MMR plans on providing access to its Patented IP and products and services in consideration of traditional sales and licensing agreements or by participation in long-term success based outcomes from clinical trials.

MMR's '212 patent is the first in a new family of patents using electronic forms of self-reporting to provide data in clinical trials. On July 9th, the day after MMR received its new clinical trials patent, a study from the University of Texas Southwestern Medical Center, published in the Journal of Oncology Practice, reported that over a six-year period, the number of patients actively using a PHR each year increased five-fold, while the number of total logins each year increased more than 10-fold. Two days later, The University of Manchester's Health eResearch Centre in the UK issued an article, Better Use of Electronic Health Records Makes Clinical Trials Less Expensive, predicting better outcomes for patients by helping them understand the treatments in both cardiovascular disease and chronic obstructive pulmonary disease.

According to MMRGlobal CEO Robert H. Lorsch, "The '212 patent is a whole new patent, not a continuation patent. This patent will allow MMR to potentially generate revenue from licensing to organizations that routinely conduct clinical trials for Big Pharma. Because clinical trials are extremely time consuming and expensive, we believe the '212 patent and additional continuation patents coming from this patent will be of significant value to the company and that this value is not reflected in previous valuations of the Company's patents, which have ranged from $600,000,000 to 1.3 billion dollars."

The '212 Patent includes 18 claims directed to methods and systems which provide for self-reporting in clinical trials. Self-reporting may be performed in various ways including receiving data from medical monitoring equipment through various forms of telemedicine services, receiving data created by healthcare providers, the entering of data from the patient including information pertaining to the tracking of taking medications and history of appointments with healthcare professionals, amongst other means. The issued patent also provides for emergency access by family, emergency personnel and physicians to a subset of records contained in a patient account in an emergency.

MyMedicalRecords, Inc. is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through the MyMedicalRecords PHR, and MMRPro and MMRProPlus document management and imaging systems for healthcare professionals. MMR currently has 13 issued U.S. health IT patents pertaining to Personal Health Records including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and its newest issued patent, 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, visit View demos and video tutorials of MMR's products and services at

Forward-Looking Statements
All statements in this release that are not strictly historical in nature, including, without limitation, intellectual property licenses, intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," and "continue," or the negative of these words. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, social, political, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including, but not limited to, customers, sources, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of patent infringement and general IP litigation; our ability to develop, license and monetize our patent portfolio for both MMR's health IT and biotechnology IP assets in the U.S. and internationally; timing of milestone payments in connection with licensing our IP; and such other risks and uncertainties as detailed in MMR's public filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033